Porownywarka
Sermorelin vs Ipamorelin side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Sermorelin | Ipamorelin |
|---|---|---|
| Kategoria | Hormon wzrostu | Hormon wzrostu |
| Znany tez jako | Geref, GRF 1-29 | IPAM, NNC 26-0161 |
| Zatwierdzony przez FDA | Tak | Nie |
| Status kliniczny | Previously FDA approved and discontinued; off-label use continues
| Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source.
|
| Czego oczekiwac | Anti-aging, hormone optimization, sleep quality | Anti-aging, muscle building, sleep quality, recovery |
| Jak dziala | Sermorelin is identified as the 1-29 fragment of human growth hormone-releasing hormone. The source reports that it engages GHRH receptors in the anterior pituitary, prompting endogenous growth hormone production and pulsatile release while remaining within normal somatostatin-mediated feedback control. | Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response. |
| Typowe dawkowanie | 200-500 mcg before bed · Once daily, typically before bed · Subcutaneous injection at bedtime | 200-300 mcg 2-3x daily · 2-3x daily |
| Dawkowanie z badań | 100-500 mcg before bed · 3-6 months typical · Subcutaneous injection at bedtime | 100-300 mcg per injection · 8-12 weeks typical · Subcutaneous injection |
| Typowy czas trwania | 3-6 months typical | 8-12 weeks typical |
| Podanie | Subcutaneous injection at bedtime | Subcutaneous injection |
| Timing | Before bed (fasted) Take on an empty stomach | Before bed or morning, fasted Fasted timing reported |
| Poziom dowodów | Zatwierdzone przez FDA | Badania kliniczne |
| Mozliwe skutki uboczne |
+6 więcej
|
+6 więcej
|
| Podsumowanie researchu | The source describes Sermorelin as having historical clinical use rather than only informal peptide-market interest. It reports FDA approval in 1990 for diagnosing GH deficiency and a 1997 approval for pediatric idiopathic GH deficiency with growth failure, with studies described as showing increased GH release and growth velocity after about six months of daily injections. It also cites work in which intravenous Sermorelin was used as a relatively specific GH-deficiency test with few false positives, and once-daily subcutaneous use supported growth in some GH-deficient prepubertal children. For adult anti-aging use, the source characterizes the evidence as much thinner, noting a 2006 editorial that favored Sermorelin conceptually over recombinant GH for age-related GH decline while acknowledging limited long-term clinical data. Commercial discontinuation in 2008 is attributed to business reasons rather than safety in the source, leaving current adult use tied to compounded, off-label contexts and limited modern trial evidence. | The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.